Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC

被引：0
|
作者：
Law, H. [1 ]
King, J. C. [1 ]
Lin, H. M. [2 ]
Curran, E. [2 ]
Wiens, J. [1 ]
Cruz, L. [3 ]
Blender, J. [4 ]
Venanzi, E. S. [4 ]
Schenk, E. [5 ]
Lin, J. J. [6 ]
机构：
[1] GO2 Lung Canc, Washington, DC USA
[2] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] ALK Posit Inc, Atlanta, GA USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Mass Gen Canc Ctr, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
care-planning; self-management; 4R;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA05.04
引用
收藏
页码：S113 / S114
页数：2
相关论文
共 50 条
  • [1] Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases
    Crino, Lucio
    Ahn, Myung-Ju
    De Marinis, Filippo
    Groen, H. J. M.
    Wakelee, Heather A.
    Hida, Toyoaki
    Mok, Tony
    Shaw, Alice
    Felip, Enriqueta
    Nishio, Makoto
    Scagliotti, Giorgio V. V.
    Branle, Fabrice
    Emeremni, Chetachi
    Sutradhar, Santosh
    Quadrigli, Massimiliano
    Zhang, Jie
    Spigel, David
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S379 - S379
  • [2] TREATMENT AND SURVIVAL PATTERNS AMONG ALK plus NSCLC PATIENTS FOLLOWING CRIZOTINIB DISCONTINUATION
    Guerin, A.
    Wakelee, H.
    Sasane, M.
    Zhang, J.
    Galebach, P.
    Jarvis, J.
    Kageleiry, A.
    Huang, Q.
    Culver, K.
    Wu, E. Q.
    Macalalad, A. R.
    VALUE IN HEALTH, 2014, 17 (03) : A73 - A73
  • [3] Real-world data on treatment patterns and survival among ALK plus NSCLC patients in Japan. Treatment patterns and survival among ALK plus NSCLC patients in Japan: Single institute experience
    Seto, T.
    Nosaki, K.
    Toyozawa, R.
    Taguchi, K.
    Edagawa, M.
    Shimamatsu, S.
    Toyokawa, G.
    Hirai, F.
    Yamaguchi, M.
    Takeda, Y.
    Takenoyama, M.
    Ichinose, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
    Wakelee, H.
    Sanborn, R.
    Nieva, J.
    Waqar, S.
    Brzezniak, C.
    Bauman, J.
    Neal, J.
    Dukart, G.
    Tan, F.
    Harrow, K.
    Liang, C.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1826 - S1826
  • [5] Diverse Characteristics of ALK plus NSCLC Patients in the United States
    Bendaly, Edmond
    Sasane, Medha
    Zhang, Jie
    Swallow, Elyse
    Macalalad, Alexander R.
    Patel, Dony
    Kageleiry, Andrew
    Galebach, Philip
    Kercheval, Jacquelyn
    Stein, Karen
    Guerin, Annie
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S376
  • [6] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
  • [8] Patient-Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK plus NSCLC Treated with Crizotinib vs Chemotherapy
    Lu, You
    Zhou, Jianying
    Chung, Chin-Hee
    Masters, Elizabeth
    Wilner, Keith
    Selaru, Paulina
    Tang, Yiyun
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1167
  • [9] SYMPTOMATIC AND ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK plus NSCLC
    Macalalad, Alexander
    Sasane, Medha
    Zhang, Jie
    Culver, Kenneth
    Dea, Katherine
    Nitulescu, Roy
    Wu, Eric
    Guerin, Annie
    NEURO-ONCOLOGY, 2014, 16
  • [10] Real-world data on treatment patterns and survival among ALK plus NSCLC patients in Japan
    Nosaki, Kaname
    Toyozawa, Ryo
    Taguchi, Kenichi
    Edagawa, Makoto
    Shimamatsu, Shin-Ichiro
    Toyokawa, Goji
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Takeda, Yoko
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345